Actinium Pharmaceuticals, Inc.
ATNMNYSE
$0.92
↑ +3.6%Jul 17 close · end-of-day
Price
1Y↓ -42.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$28.8M
Enterprise Value
-$13.3M
P/E
—
P/S
—
P/B
12.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$23.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-1018.7%
ROIC
—
Debt / Equity
—
Net Cash
$42.1M
Return 1Y
-43.1%
Company profile
Actinium Pharmaceuticals, Inc. focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning. The company also offers clinical and preclinical development programs that utilize multiple isotopes.
- CEO
- Sandesh Seth
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- New York
- Website
- actiniumpharma.com
Earnings
ATNM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.18↓ -64.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $1.1M | $1.0M | $81,000.00 | — | $90,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$22.4M | -$25.0M | -$34.1M | -$51.9M | -$42.1M | -$36.2M |
| Net income | -$22.2M | -$24.8M | -$33.0M | -$48.8M | -$38.2M | -$33.9M |
| Diluted EPS | — | -$1.20 | -$1.37 | -$1.83 | -$1.27 | -$1.09 |
| Operating cash flow | -$21.6M | -$20.9M | $8.6M | -$47.3M | -$33.1M | -$24.6M |
| Free cash flow | -$21.9M | -$21.0M | $8.3M | -$47.5M | -$33.1M | -$24.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -2182.2% | -3311.1% | -64098.8% | — | -40274.4% |
| Net margin | — | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $90,000.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$12.4M | -$12.6M | -$7.5M | -$16.6M | -$7.5M | -$5.7M | -$6.4M | -$5.9M |
| Net income | -$11.4M | -$11.6M | -$6.7M | -$15.9M | -$6.9M | -$5.1M | -$5.9M | -$5.5M |
| Diluted EPS | -$0.38 | -$0.37 | -$0.21 | -$0.51 | -$0.22 | -$0.16 | -$0.20 | -$0.18 |
| Operating cash flow | -$8.0M | -$12.0M | -$5.8M | -$7.6M | -$5.4M | -$6.3M | -$5.3M | -$5.9M |
| Free cash flow | -$8.0M | -$12.0M | -$5.8M | — | — | — | — | -$5.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -6324.4% | — | — |
| Net margin | — | — | — | — | — | -5701.1% | — | — |
Company news
Jun 3, 2026
- 47d agoActinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancerfinance.yahoo.com
- 47d agoActinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Modelsfinance.yahoo.com
Jun 1, 2026
- 49d agoActinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Developmentfinance.yahoo.com
- 49d agoActinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugatesfinance.yahoo.com
May 29, 2026
- 51d agoActinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programsfinance.yahoo.com
- 51d agoActinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Noticefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-18 | SETH SANDESH· Chief Executive Officer | Tax withholding | 120,900 | $1.71 | $206,739.00 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.